A six-year-old girl signed up to fix a headache-sized mutation in her DNA.
She never came home.
This is the story nobody was supposed to see.
Her name, for privacy, was "Mei."
She had Snijders Blok-Campeau syndrome — a condition so rare it affects just 237 people on Earth.
One letter in her DNA was wrong. A T where a C should be.
Mild cognitive impairment. A slightly bigger head. That's it.
Most people with it live normal, full lifespans.
Her parents were told about a cutting-edge fix.
Base editing. A sharper, more precise cousin of CRISPR.
Price tag: over $800,000, self-funded, out of pocket.
No insurance. No safety net. Just hope.
Last March, doctors at Xinhua Hospital injected trillions of viral particles into Mei's spine.
Designed to cross into her brain. Designed to rewrite the faulty code.
One week later, her immune system collapsed.
She died.
Here's where it gets disturbing.
The lead researcher, neuroscientist Zilong Qiu, kept working.
Months later, he published a paper in Nature — one of the most prestigious journals on the planet — on related animal studies.
Mei's death: not mentioned.
Her family's funding: not mentioned.
The only hint was one vague line about how "bridging the gap between preclinical research and clinical translation remains a significant challenge."
That's it. That's all the world was told.
An investigation by Science and Retraction Watch just cracked this open, and Mei's case was never even updated in the public clinical trials registry.
Seven independent experts in genetics, virology and bioethics reviewed the case.
Their verdict:
Base editing is supposed to be the future — precise, safe, life-changing.
But scientists worldwide are racing to be first.
And Mei didn't have a fatal disease.
She had a manageable one.
Which is exactly why bioethicists are now asking the hardest question of all:
should experimental gene surgery ever be tested on a child who didn't need to gamble her life to begin with.
That's all for now!
